Filing Flows › Bolt Biotherapeutics (BOLT) › Q3 2025
Bolt Biotherapeutics (BOLT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Bolt Biotherapeutics (BOLT) reported revenue of $2.2M for the third quarter 2025 (Q3 2025), +90% from a year earlier and +20% from the quarter before. Operating margin was -355.1%, net loss $7.1M (329.4% of revenue).
Bolt Biotherapeutics, Q3 2025: revenue $2.2M (+90% year over year), operating margin -355.1%, net loss $7.1M, operating cash flow −$9.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.2M | +20% | +90% |
| Operating profit | −$7.7M | — | — |
| Net earnings | −$7.1M | — | — |
| Operating cash flow | −$9.7M | — | — |
What changed
Revenue was $2.2M in Q3 2025, up 90% year over year and up 20% from the previous quarter.
Operating costs exceeded revenue by $7.7M, an operating margin of -355.1%. Total costs fell 44% while revenue rose 90%. The quarter ended with a net loss of $7.1M, narrower than the previous quarter's $8.6M loss.
Operating cash flow was −$9.7M. Non-cash charges added back $290K of depreciation and amortization and $407K of share-based compensation. Working capital and other items used $3.3M. Capital expenditures of $72K exceeded it, leaving free cash flow of −$9.8M.
Questions
What was Bolt Biotherapeutics' revenue in the third quarter 2025?
Bolt Biotherapeutics (BOLT) reported revenue of $2.2M for the third quarter 2025 (Q3 2025), +90% from a year earlier and +20% from the quarter before.
Was Bolt Biotherapeutics profitable in the third quarter 2025?
Operating loss was $7.7M (-355.1% of revenue) and net loss $7.1M.